Zentalis Pharmaceuticals (ZNTL) EPS (Weighted Average and Diluted) (2022 - 2025)
Historic EPS (Weighted Average and Diluted) for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$0.37.
- Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) rose 3392.86% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.07, marking a year-over-year increase of 1686.75%. This contributed to the annual value of -$2.33 for FY2024, which is 4779.58% up from last year.
- According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) is -$0.37, which was up 3392.86% from -$0.37 recorded in Q2 2025.
- Zentalis Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $0.14 for Q1 2024, and its period low was -$1.85 during Q2 2023.
- Its 4-year average for EPS (Weighted Average and Diluted) is -$0.85, with a median of -$0.83 in 2023.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 11308.41% in 2024, then tumbled by 57857.14% in 2025.
- Quarter analysis of 4 years shows Zentalis Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.92 in 2022, then grew by 9.78% to -$0.83 in 2023, then rose by 19.53% to -$0.67 in 2024, then soared by 44.6% to -$0.37 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.37 in Q3 2025, compared to -$0.37 in Q2 2025 and -$0.67 in Q1 2025.